Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of June 2026, specifically reporting on a private placement transaction entered into on June 18, 2026. The Company, a foreign private issuer based in Tel Aviv, Israel, executed a Securities Purchase Agreement with an accredited investor to raise capital through the issuance of American Depositary Shares (ADSs) and warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $6 million expected from the initial offering, before deducting placement agent fees and offering expenses.
- Potential Additional Proceeds: Approximately $13.4 million if Series A-1 and Series A-2 warrants are fully exercised on a cash basis.
- Offering Structure: Sale of 8,571,429 Offering ADSs (or Pre-Funded Warrants) at a combined purchase price of $0.70 per ADS (or $0.699 per Pre-Funded Warrant).
- Warrant Terms:
- Series A-1 Warrants: Exercise price of $0.86 per ADS; exercisable immediately; 5-year term.
- Series A-2 Warrants: Exercise price of $0.70 per ADS; exercisable immediately; 18-month term.
- Placement Agent Fees: H.C. Wainwright & Co. received a cash fee equal to 7.5% of gross proceeds plus expense reimbursement, plus warrants to acquire up to 514,286 ADSs at $0.875 per ADS.
Material Changes and Restrictions
The filing details significant capital structure changes and contractual restrictions imposed by the private placement:
- Issuance Restrictions: The Company is prohibited from issuing new equity or filing registration statements for 90 days following the Effectiveness Date, with a one-year prohibition on "Variable Rate Transactions."
- Beneficial Ownership Limit: Warrant holders cannot exercise warrants if the resulting ownership would exceed 4.99% of the Company's outstanding ordinary shares or voting rights.
- Registration Rights: The Company must file a registration statement for resale of the securities within 15 calendar days of June 18, 2026, and use commercially reasonable efforts to make it effective within 45 to 75 days.
Outlook, Risks, and Management Commentary
The filing does not provide specific operational guidance, revenue forecasts, or management commentary regarding clinical progress or product development. The primary focus is the financing event. Key risks and contingencies include:
- Exercise Uncertainty: No assurance is given that the Series A-1 or Series A-2 warrants will be exercised, meaning the potential $13.4 million in additional proceeds may not materialize.
- Dilution: The issuance of ADSs and warrants, along with the placement agent warrants, will result in dilution to existing shareholders.
- Liquidity Constraints: The 90-day lock-up on new issuances limits the Company's ability to raise additional capital quickly if market conditions change.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting the 7.5% placement fee and other expenses.
- Confirm the "Effectiveness Date" of the registration statement to determine the start of the 90-day issuance lock-up period.
- Review the full text of the Securities Purchase Agreement (Exhibit 1.1) for specific representations, warranties, and termination provisions.
- Monitor the Company's cash burn rate to assess if the $6 million in proceeds is sufficient to fund operations until the next potential capital raise.
- Check for any subsequent filings regarding the exercise of the Series A-1 or A-2 warrants.